Developing Story
PCSK9 DNA-Based Cholesterol Treatment
Researchers developed a DNA-based treatment targeting PCSK9 that reduced the protein by 87% in human liver cells and lowered cholesterol by 47% in mice after a single injection, offering a potential statin alternative (ScienceDaily, September 10). The treatment remains in early-stage animal/cell research.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
Researchers have designed a new DNA-based treatment targeting PCSK9, a protein closely tied to high LDL cholesterol and atherosclerosis, as an alternative to statins (ScienceDaily, September 10).
## Key Details
- The most effective molecule reduced PCSK9 protein by 87% in human liver cells (ScienceDaily, September 10).
- Cholesterol was lowered by 47% in genetically modified mice following a single injection (ScienceDaily, September 10).
- The approach targets PCSK9 directly at the DNA level, differentiating it from existing PCSK9-inhibiting antibody drugs and statins already on the market.
## Strategic Significance
If validated in human trials, a single-injection DNA-based PCSK9 treatment could represent a durable, potentially one-time therapeutic alternative to daily statin regimens or repeated antibody injections, with significant implications for cardiovascular disease treatment markets and pharmaceutical competitive positioning. This is an early-stage research finding (mouse models, human liver cells in vitro) and has not yet progressed to human clinical trials.
## Entities to Watch
- Progression to human clinical trials
- Competing PCSK9-targeting therapies (existing antibody drugs like evolocumab/alirocumab)
- Pharmaceutical company licensing or partnership announcements